Down syndrome (DS) children have an increased incidence of transient abnormal myelopoiesis (TAM) and acute megakaryoblastic leukemia (AMKL). The majority of these cases harbor somatic mutations in the GATA1 gene, which results in the loss of full-length of GATA1, accordingly only a truncated isoform of GATA1 that lacks the N-terminal 83 amino acids (GATA1-S) remains. We found through genetic studies in 106 TAM patients that internally deleted GATA1 proteins (GATA1-IDs) lacking amino acid residues 77-119 or 74-88 (created by splicing mutations) contributed to the genesis of TAM in six patients. Analyses of GATA1-deficient embryonic megakaryocytic progenitors revealed that the GATA1 function in growth restriction was disrupted in GATA1-IDs. In contrast, GATA1-S rather promoted megakaryocyte proliferation more profoundly than that induced by GATA1-deficiency.
Introduction
Down syndrome children are known to have a high risk of developing transient abnormal myelopoiesis (TAM) and subsequent acute megakaryoblastic leukemia (DS-AMKL). [1] [2] [3] [4] Blast cells in the majority of TAM and DS-AMKL patients have mutations in the second exon of the GATA1 gene. 5, 6 The mutations turn off the production of full-length GATA1, instead N-terminally truncated GATA1 protein (GATA1-S) was translated from the second methionine at codon-84, which is identical to the truncated GATA1 isoform found in the healthy human. 7 In contrast, only a few AMKL cases have been reported to harbor 21-disomy blasts with the GATA1 mutation. 8.9 Therefore, GATA1-S is believed to be a prerequisite for the pathogenesis of TAM and DS-AMKL in Down syndrome children, and unrestricted proliferation of megakaryocytic progenitors in DS-AMKL is provoked by a mechanism involving GATA1-S. However, the molecular mechanism how GATA1-S contributes to the genesis of TAM and DS-AMKL remains elusive.
GATA1 regulates the proliferation of immature megakaryocytic progenitors. Indeed, active proliferation of immature megakaryocytic progenitors derived from GATA1-deficient mouse embryos is restricted by introduction of wild-type GATA1, but not by GATA-S.
10
GATA1-deficient mice rescued with transgenic expression of GATA1-S (or GATA1-ΔNT) are found to exhibit hyper-megakaryopoiesis in a limited embryonic and postnatal period, resembling the phenotype in human TAM cases.
11
On the contrary, a report that utilizes targeting mice expressing GATA1 protein with a deletion of N-terminal 64 amino acids but retaining intact 65th to 83rd amino acid residues has demonstrated that the embryos display a transient megakaryocytic phenotype only during the early embryonic stage but not in late embryonic and post-natal stages. 12 We surmise that this difference may simply be a result of missing the region corresponding to the 65th to 83rd amino acids.
For personal use only. on April 14, 2017 . by guest www.bloodjournal.org From Here, we have identified novel GATA1 mutants with internal deletions (IDs) of either amino acid residues 77th to 119th or 74th to 88th (GATA1-IDs) in six patients. We found that the GATA1-IDs lost their activity in the regulation of magakaryocyte growth. These results demonstrate that disruption of ID regions is implicated in the pathogenesis of TAM.
Methods
This study was approved by the Ethics Committee of Hirosaki University Graduate School of Additional information can be found in supplemental methods.
Results and Discussion
Between 2003 and 2010, we screened GATA1 mutations by direct sequencing utilizing cDNAs prepared from TAM blasts provided by 106 Down syndrome patients upon request from referring hospitals. Acquired GATA1 mutations were detected in 99 (93.4%) patients (supplemental Table 1 ). The majority of the mutations resulted in the GATA1-S mutant protein, which lacks the entire N-terminal transactivation domain. Importantly, we found new mutations harboring ID of 43 and 15 amino acids in five patients (#37, 67, 68, 70, and 80) and one patient (#71), respectively. We refer these mutants to as GATA1-ID type-1 and GATA1-ID type-2, respectively ( Figure 1A ). Clinical features in TAM patients with GATA1-ID mutations were shown in supplemental Table 2 . All of these patients showed high white blood cell counts in the peripheral blood, which is known to be a risk factor for early death. 13 For personal use only. on April 14, 2017. by guest www.bloodjournal.org From
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We determined the genomic DNA sequences of these cases. As shown in Figure 1B , the mutations in GATA1-ID type-1 were located in a site immediately 3' of the consensus motif for a splice donor site "AGGT" 14 To examine whether the GATA1-ID proteins were produced from the mutant alleles, we performed immunoblotting analysis with two distinct antibodies recognizing the C-terminus and the 66th to 78th amino acid region, respectively. We detected GATA1-ID type-1 protein in addition to GATA1-S in the cells transfected with the mini-genes harboring either Ins 2-bp, Del 2-bp or Del 7-bp T>A mutations, whereas only GATA1-ID type-2 protein was expressed upon transfection of the mini-gene with Del 21-bp mutation ( Figure 1C) . Consistent with the mini-gene results, a significant amount of GATA1-ID type-1 protein and GATA1-S had accumulated in the patients #80 and #37, whereas only GATA1-S was detected in the TAM blasts of patient #86 who had only a short transcript skipping exon-2 due to a point mutation in the exon-2-intron-2 boundary ( Figure 1D ). Thus, splicing errors were occurred in GATA1-ID type-1 and type-2 patients, leading to the production of GATA1-ID proteins.
For
We next examined how GATA1-ID proteins affect the proliferation of embryonic megakaryocytic progenitors. We retrovirally transduced GATA1-S and GATA1-ID mutants into lineage-negative cells derived from megakaryocyte-specific Gata1-deficient
(Gata1
ΔneoΔHS ) embryos 15 and induced differentiation toward the megakaryocytic lineage.
The number of CD41 + CD61 + megakaryocytes was significantly higher in cases transduced with GATA1-ID proteins than that with wild-type GATA1 in spite of almost equivalent expression levels of GATA1 proteins (Figure 2A-C) .
GATA1-S-transduced cells unexpectedly acquired a hyper-proliferative potential compared to mock cells, probably due
to an unknown function that resides in the GATA1 N-terminal region ( Figure 2B -C).
We next analyzed cell proliferation using the DS-AMKL cell line KPAM1, in which GATA1-S was predominantly expressed with a very low level of full-length GATA1 ( Figure   2D ). 16 Upon transduction with full-length GATA1 retrovirus, proliferation of KPAM1 cells was markedly reduced. In contrast, GATA1-ID type-1 and type-2 restricted moderately the proliferation of KPAM1 cells, but the restriction activity was significantly stronger than that of GATA1-S ( Figure 2E-F) . These results thus demonstrate that the ID regions indeed contribute to the regulation of AMKL cell proliferation.
Our newly identified GATA1-ID mutants have highlighted a much narrower set of sequences responsible for the pathogenesis of TAM than has previously been suggested by the loss of the N-terminal sequence as in GATA1-S. The missing region identified by the GATA1-ID proteins contains a consensus motif (LxCxE, amino acids 81-85) essential for the interaction with pRb, 17 which is also lost in GATA1-S. Interaction with hypo-phosphorylated pRb-E2F complex has been reported to be important for GATA1 to support the normal proliferation and differentiation of erythroid progenitors. 17 Consistent with this notion, GATA1-S failed to repress E2F activation, which was followed by activation of mTOR signaling in the GATA1-S fetal megakaryocytes and DS-AMKL cells. Table) . Human erythroleukemia cells (HEL, lane 1) were used as a control for GATA1 and GATA1-S. For personal use only. on April 14, 2017 . by guest www.bloodjournal.org From
